Naomasa Kakiya

Aug 6, 2024 | science.org | Naoto Watamura |Daoyuan Dong |Leslie K. Ferrarelli |Naomasa Kakiya

Editor’s summaryThe accumulation of amyloid-β in the brain is associated with progressive cognitive impairment in Alzheimer’s disease. Watamura et al. found that a treatment commonly used to treat a symptom of Parkinson’s disease also induced the breakdown of amyloid-β. In mice, dopamine release in the brain increased the abundance and activity of the enzyme neprilysin, which degraded amyloid-β specifically in the working memory center of the brain.